Overview
- Bolshakov, K.V. et al. (2005) Neuropharm., 49, 144.
- Bolshakov, K.V. et al. (2003) J. Neurochem., 87, 56.
- Zaitsev, A.V. et al. (2015) J. Neurosci. Res., 93, 454.
Up to 200 mM in DMSO. Centrifuge all product preparations before use (5,000 x g for 1 min).
Alomone Labs IEM-1921 inhibits NMDA (NR1+NR2A) receptors expressed in Xenopus oocytes.A. Representative time course of NR1/NR2A currents, elicited by transient stimulations with 20 µM glutamate + 20 µM glycine every 50 sec, while membrane potential was held at -60 mV, and significantly inhibited by 10 μM IEM-1921 (#I-180).
B. Superimposed current traces from the recording shown in A, following application of control and 10 μM IEM-1921. Transient stimulation is indicated by an arrow.
- Liu, J. et al. (2019) Front. Neurosci.,13, 43.
- Zaitsev A.V. et al. (2015) J. Neurosci. Res., 93, 454.
- Vataev S.I. et al. (2020) Neurosci. Behav. Physi., 50, 374.
N-methyl-D-aspartate (NMDA) receptors, a family of L-glutamate receptors, play an important role in the central nervous system. Activation of NMDARs leads to cytosolic free intracellular calcium ([Ca2+]i) increase and for synaptic plasticity1.
Abnormal activity of NMDA receptors is associated different neurodegenerative disorders such as Alzheimer’s, Huntington’s, Parkinson’s disease and the etiology of epilepsy1.
IEM-1921, also known as 1-phenylcyclohexylamine, is a selective blocker of NMDA receptors. In chronic experiments on Wistar and Krushinskii–Molodkina rats it was found that IEM-1921 (5mg/kg) acts as anticonvulsant. IEM-1921 decreased the duration of convulsions by 82% and prevent neural abnormalities in the brain2-3.
IEM-1921 (#I-180) is a highly pure, synthetic, and biologically active compound.
Powered by Bioz
